Evidence map›Paper›PMID 31451106›Full record

ArticleActa neuropathologica communications2019

Downregulation of Nodal inhibits metastatic progression in retinoblastoma.

Laura Asnaghi, David T White, Lynn Yoon, Antoinette Price, Grace Y Lee, Arpan Sahoo, Jeff S Mumm, Charles G Eberhart

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Laura AsnaghiDepartment of Pathology, Johns Hopkins University, School of Medicine, Smith Building, 400 N. Broadway Avenue, Room 4029, Baltimore, MD, 21287, USA. LauraAsnaghi1@aol.com.ORCID 0000-0002-1066-3639
David T WhiteDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Lynn YoonDepartment of Pathology, Johns Hopkins University, School of Medicine, Smith Building, 400 N. Broadway Avenue, Room 4029, Baltimore, MD, 21287, USA.
Antoinette PriceDepartment of Pathology, Johns Hopkins University, School of Medicine, Smith Building, 400 N. Broadway Avenue, Room 4029, Baltimore, MD, 21287, USA.
Grace Y LeeDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Arpan SahooDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Jeff S MummDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Charles G EberhartDepartment of Pathology, Johns Hopkins University, School of Medicine, Smith Building, 400 N. Broadway Avenue, Room 4029, Baltimore, MD, 21287, USA. ceberha@jhmi.edu.
Johns Hopkins University · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
Targeting Nodal/TGF-Beta pathway to inhibit invasion and growth of retinoblastomaR21CA229919 · NCI · JOHNS HOPKINS UNIVERSITY · PI EBERHART, CHARLES G · 2018 to 2019
$386k
NCI NIH HHS R21 CA229919NEI NIH HHS P30 EY001765
6 · The paper itself

Abstract

Retinoblastoma is the most common intraocular malignancy in children. We previously found that the ACVR1C/SMAD2 pathway is significantly upregulated in invasive retinoblastoma samples from patients. Here we studied the role of an ACVR1C ligand, Nodal, in regulating growth and metastatic dissemination in retinoblastoma. Inhibition of Nodal using multiple short hairpin (shRNAs) in WERI Rb1 and Y79 retinoblastoma cell cultures reduced growth by more than 90%, as determined by CCK-8 growth assay. Proliferation was also significantly inhibited, as found by Ki67 assay. These effects were paralleled by inhibition in the phosphorylation of the downstream effector SMAD2, as well as induction of apoptosis, as we observed more than three-fold increase in the percentage of cells positive for cleaved-caspase-3 or expressing cleaved-PARP1. Importantly, we found that downregulation of Nodal potently suppressed invasion in vitro, by 50 to 80%, as determined by transwell invasion assay (p = 0.02). Using an orthotopic model of retinoblastoma in zebrafish, we found 34% reduction in the ability of the cells to disseminate outside the eye, when Nodal was knocked down by shRNA (p = 0.0003). These data suggest that Nodal plays an important role in promoting growth, proliferation and invasion in retinoblastoma, and can be considered a new therapeutic target for both primary tumor growth and metastatic progression.

Indexed as

Disease ProgressionAnimalsCell ProliferationDown-RegulationHumansMiceNeoplasm InvasivenessNodal ProteinRetinal NeoplasmsRetinoblastomaXenograft Model Antitumor AssaysZebrafishNodal ProteinNODAL protein, humanInvasionNodalProliferationRetinoblastoma

Identifiers

PMID31451106
PMCPMC6709548
OpenAlexW2971307441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.